

This policy applies to the following:

Standard Control (SF)	Value (VF)	ACSF Chart (ACSFC)	Medical Benefit	Medicare Part B	Reference #
Preferred Drug Plan Design (PDPD)	Managed Medicaid Template (MMT)	SF Chart (SFC)	Medical Benefit: Biosimilars First	Medicare Part B: Biosimilars First	4516-D
Advanced Control Specialty (ACSF)	Marketplace (MF)	VF Chart (VFC)	Medical Benefit: Add-on	Medicare Part B: Add-on	
Balanced (BF)	✓ New to Market (NTM)	IVL	Medical Benefit: Managed Medicaid	Aetna Health Exchange (AHE)	

EXCEPTIONS CRITERIA UKONIQ

PREFERRED PRODUCT FOR FOLLICULAR LYMPHOMA: COPIKTRA

PREFERRED PRODUCT FOR MARGINAL ZONE LYMPHOMA: IMBRUVICA

POLICY

This policy informs prescribers of preferred products and provides an exception process for UkonIQ through prior authorization.

I. PLAN DESIGN SUMMARY

This program applies to the PI3K inhibitor products specified in this policy. Coverage for UkonIQ is provided based on clinical circumstances that would exclude the use of the preferred products and may be based on previous use of a product. The coverage review process will ascertain situations where a clinical exception can be made. This program applies to all members requesting treatment with UkonIQ.

Each referral is reviewed based on all utilization management (UM) programs implemented for the client.

Table. PI3K inhibitors

Indication	Preferred Product*	Targeted Product
Follicular lymphoma	• Copiktra (duvelisib)	• UkonIQ (umbralisib)
Marginal zone lymphoma	• Imbruvica (ibrutinib)	• UkonIQ (umbralisib)

*: Medications considered formulary or preferred on your plan may still require a clinical prior authorization review.

II. EXCEPTION CRITERIA

Coverage of UkonIQ is provided if the member has had a documented intolerable adverse event or contraindication to the preferred product specific to the member's indication.

REFERENCES

1. Copiktra [package insert]. Needham, MA: Verastem, Inc.; July 2019.
2. Imbruvica [package insert]. Sunnyvale, CA: Pharmacyclics LLC; December 2020.
3. UkonIQ [package insert]. Edison, NJ: TG Therapeutics, Inc.; February 2021.